Innoviva (INVA) Net Cash Flow Growth (3y) (2013 - 2026)
Innoviva (INVA) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,725.60 Bn | 68,725.31 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,953.19 Bn | 1,953.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 472.73 Bn | 467.94 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 123.52 Bn | 116.27 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 69.74 Bn | 60.99 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - | - |
| 8 | Argenx Se | 56.42 Bn | 51.24 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.76 Bn | 37.76 Bn | - | - |
| 10 | Innoviva | 1.60 Bn | 998.03 Mn | 75.83 Mn | 33.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33.04% |
| Sep 30, 2025 | 19.99% |
| Jun 30, 2025 | 5.51% |
| Mar 31, 2025 | -2.58% |
| Sep 30, 2024 | 37.55% |
| Jun 30, 2024 | 29.29% |
| Mar 31, 2024 | -34.19% |
| Sep 30, 2023 | -54.41% |
| Jun 30, 2023 | -22.05% |
| Mar 31, 2023 | -58.60% |
| Sep 30, 2022 | 47.42% |
| Jun 30, 2022 | -4.55% |
| Mar 31, 2022 | 77.45% |
| Sep 30, 2021 | -42.35% |
| Jun 30, 2021 | -81.59% |
| Mar 31, 2021 | 40.74% |
| Dec 31, 2020 | -52.92% |
| Sep 30, 2020 | 82.97% |
| Jun 30, 2020 | 57.42% |
| Mar 31, 2020 | 20.92% |